Bristol’s Opdivo Continues Slide, But First-Line Lung Offers Optimism

Sales of the Bristol PD-1 inhibitor dropped 9% year-over-year but the company says approvals in first-line NSCLC are off to a good start. Q2 saw growth for Eliquis and Revlimid despite pandemic impact.

Bristol-Myers-Squib_685347493_1200.jpg
Bristol sees positive early trends for the Opdivo/Yervoy combo in first-line lung cancer

More from Earnings

More from Business